TN2018000312A1 - Compositions and methods for treating rheumatoid arthritis - Google Patents

Compositions and methods for treating rheumatoid arthritis

Info

Publication number
TN2018000312A1
TN2018000312A1 TNP/2018/000312A TN2018000312A TN2018000312A1 TN 2018000312 A1 TN2018000312 A1 TN 2018000312A1 TN 2018000312 A TN2018000312 A TN 2018000312A TN 2018000312 A1 TN2018000312 A1 TN 2018000312A1
Authority
TN
Tunisia
Prior art keywords
rheumatoid arthritis
compositions
methods
treating rheumatoid
treating
Prior art date
Application number
TNP/2018/000312A
Other languages
English (en)
Inventor
Deborah Bauer
Alexander Boddy
Neil Graham
Yong Lin
Janie Parrino
Rahul Patel
Adelsberg Janet Van
Hoogstraten Hubert Van
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of TN2018000312A1 publication Critical patent/TN2018000312A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP/2018/000312A 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis TN2018000312A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
TN2018000312A1 true TN2018000312A1 (en) 2020-01-16

Family

ID=58387910

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2018/000312A TN2018000312A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Country Status (18)

Country Link
US (1) US20190100585A1 (https=)
EP (1) EP3426295A1 (https=)
JP (2) JP7166925B2 (https=)
KR (3) KR20260049875A (https=)
CN (1) CN109069642A (https=)
AU (2) AU2017229364A1 (https=)
BR (1) BR112018067851A2 (https=)
CA (1) CA3016880A1 (https=)
CL (1) CL2018002559A1 (https=)
CR (1) CR20180465A (https=)
EA (1) EA201892005A1 (https=)
IL (2) IL261515B2 (https=)
MX (2) MX2018010815A (https=)
PH (1) PH12018501894A1 (https=)
SG (2) SG10202012182YA (https=)
TN (1) TN2018000312A1 (https=)
TW (3) TW202419103A (https=)
WO (1) WO2017155990A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
SG11202101674QA (en) * 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) * 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
MX377190B (es) * 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Also Published As

Publication number Publication date
CA3016880A1 (en) 2017-09-14
TWI747885B (zh) 2021-12-01
TW201808993A (zh) 2018-03-16
SG10202012182YA (en) 2021-01-28
JP2023011711A (ja) 2023-01-24
JP7745529B2 (ja) 2025-09-29
SG11201807614SA (en) 2018-10-30
TW202419103A (zh) 2024-05-16
MX2023014841A (es) 2024-01-15
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
TWI819435B (zh) 2023-10-21
US20190100585A1 (en) 2019-04-04
KR20260049875A (ko) 2026-04-14
TW202239767A (zh) 2022-10-16
JP7166925B2 (ja) 2022-11-08
CN109069642A (zh) 2018-12-21
EA201892005A1 (ru) 2019-02-28
EP3426295A1 (en) 2019-01-16
IL261515A (en) 2018-10-31
IL308539A (en) 2024-01-01
CR20180465A (es) 2019-03-04
MX2018010815A (es) 2019-01-10
NZ746988A (en) 2023-10-27
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
JP2019507775A (ja) 2019-03-22
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
KR20180114955A (ko) 2018-10-19
AU2024203011A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MY177212A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2022003273A (es) Anticuerpos anti-tau y metodos de uso.
ZA201905866B (en) Anti-c5 antibodies and uses thereof
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
SG10201901057UA (en) Anti-pd-l1 antibodies
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
MY176855A (en) Anti-jagged1 antibodies and methods of use
TW201613967A (en) Interferon alpha and omega antibody antagonists
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
EP4238994A3 (en) Compositions and methods of treating lupus nephritis
TN2017000534A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
SG10201811475YA (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
WO2015116852A8 (en) Methods for treating rheumatoid arthritis by administering an il-6r antibody
UA93228U (uk) Спосіб отримання "нанополіолефінів" - нанокомпозитів поліолефінів та співполімерів поліолефінів